Background:
Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular
Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict
interaction between environment and genetic. The mechanisms linking these two diseases are
complex, multifactorial and not entirely understood, influencing the therapeutic approach.
COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular
co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class
of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory,
epidemiological, and human clinical studies point the important effects on CVD risk
prevention.
Objective:
This review aims to provide up-to-date information on the ability of Flavonoids to
reduce the CVD risk.
Conclusion:
Current studies support the potential of Flavonoids to prevent the risk of CVD.
Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids
for managing CVD comorbidity in COPD.
Does the Concept of Loss Orient Risk Prevention Policy?
